Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults

17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...

Read more →

Baqsimi (nasal glucagon), rescue treatment for severe hypoglycaemia now covered in British Colombia, Alberta & Saskatchewan

27 April 2022 - Lilly Canada is pleased to announce that as of 5 April 2022, Baqsimi (glucagon nasal powder) ...

Read more →

Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation

21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...

Read more →

AbbVie announces provincial reimbursement for Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia in Alberta, Saskatchewan, British Columbia and Manitoba

24 February 2022 - AbbVie announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta (venetoclax) in combination ...

Read more →

Drug funded for people with spinal muscular atrophy

15 February 2022 - The provincial government is covering costs for risdiplam, or Evrysdi, the medication used to treat a severe ...

Read more →

B.C. woman petitions province to cover cost of 'life-changing' migraine medication

29 March 2021 - Christina Sall says Aimovig is the only drug that helps her, but it costs her more than ...

Read more →

B.C. family nearing finish in race to raise $2.8 million to treat baby's rare disease

8 August 2020 - Parents hope funds will pay for expensive therapy not approved in Canada for type 1 spinal muscular ...

Read more →

B.C. eye-injection program ‘clouded in secrecy’

28 January 2020 - Two dozen ophthalmologists are accusing the B.C. government of failing to properly investigate concerns that a ...

Read more →

B.C. funding decision on pricey drug leaves teen with rare disease facing 'scary' future

13 January 2020 - Miles Ambridge just misses cut-off age to access Spinraza, a potentially life-changing treatment. ...

Read more →

B.C. wants federal health funding lift before national pharmacare program

3 December 2019 - B.C. wants more money from Ottawa for health care before a national pharmacare program is created, ...

Read more →

Erosion of physician and patient treatment choice continues - Alliance for Safe Biologic Medicines raises concerns for patients as British Columbia expands biologics forced switching policy

10 September 2019 - On 5 September, the Government of British Columbia announced that it would be forcibly switching 1,700 patients ...

Read more →

New drug helps extend survival rate of men with advanced prostate cancer: B.C. Cancer Agency study

10 June 2019 - At two years, advanced prostate cancer patients taking the trial drug, in addition to their standard treatment, ...

Read more →

Patients, physicians raise concerns with BC biosimilar non-medical switching policy

6 June 2019 - On 27 May, the Government of British Columbia announced a policy that will forcibly switch thousands ...

Read more →

Canadian Biosimilars Forum applauds B.C. Government's landmark decision to enhance adoption of biosimilars and calls on remaining provinces to follow

27 May 2019 - The Canadian Biosimilars Forum today commends the Government of British Columbia for taking a decisive step ...

Read more →

BC PharmaCare’s Biosimilars Initiative an important step towards improving patient access to safe and effective medicines

27 May 2019 - Biosimilars Initiative implementation could contribute to significant cost savings for the BC health care system. ...

Read more →